Ipilimumab Improves Survival for Patients with Metastatic Melanoma

At Sunday’s Plenary Session, a landmark study provided new data that have implications for changing clinical practice. Steven O’Day, MD, of the Angeles Clinic and Research Institute, reported that ipilimumab alone or in combination with vaccine increased overall survival (OS) in patients with unresectable stage III/IV melanoma for whom previous treatment had failed (Abstract 4).

“This is an historic first — the first phase III randomized study showing improvement in median and long-term survival in patients with metastatic melanoma,” Dr. O’Day said. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), is an immune therapy directed against T-cells.

The study evaluated two therapeutic approaches — ipilimumab and vaccine therapy with gp100 alone and in combination. The double-blind study randomly assigned patients to receive ipilimumab (137 patients), ipilimumab and gp100 (403 patients), or gp100 alone (136 patients). All patients were required to be HLA-A2 positive. Ipilimumab 3 mg/kg was given once every 3 weeks for four cycles. The vaccine gp100 was given at a dose of 1 mg, also every 3 weeks for four cycles. The primary endpoint of the study was overall survival (OS). After 12 months, 46% of patients receiving ipilimumab alone, 44% receiving ipilimumab plus gp100, and 25% receiving gp100 were still alive. The hazard ratio (HR) for OS demonstrated a 32% to 34% reduction in the risk for death in the two ipilimumab arms compared with the vaccine arm alone (p = 0.0026 for ipilimumab alone versus gp100; p = 0.0004 for the combination versus gp100)
The disease control rate, a composite endpoint of complete response, partial response, and stable disease, was 28.5% for the ipilimumab arm (p = 0.0002 versus gp100); 20.1% for the combination arm (p = 0.0179 versus gp100); and 11% for the gp100 arm. The best overall response rates were 10.9% for patients receiving ipilimumab, 5.7% for the combination, and 1.5% for gp100 alone. For every endpoint evaluated, ipilimumab was superior to either the combination or gp100 alone.

New Treatment Option

“These results are exciting because patients with melanoma have few treatment options,” Dr. O’Day said. “After 30 years of failed studies, we finally have an option that shows a significant increase in overall survival, an endpoint that many oncology studies strive for. This new class of inhibitors that overcome T-cell suppression offers hope to melanoma patients and oncologists alike.”

Adverse events were predominantly immune response–related and included rash, colitis, diarrhea, and hepatitis. Most were manageable and reversible, Dr. O’Day said. More serious immune-related grade 3 or 4 toxicities occurred in 10% to 13% of patients receiving ipilimumab. The rates of grade 3 or 4 events at specific organ sites were dermatologic (= 2.1%), gastrointestinal (= 7.6%), liver (1.1%), and pituitary (= 2.3%). Across multiple studies, these side effects correlated with clinical outcomes and could indicate that therapy with ipilimumab is working. For patients with metastatic melanoma with few options, such as interleukin (IL-2) and dacarbazine, ipilimumab could become the standard of care, Dr. O’Day said.


Captavi QixSuite™ - Hosted Marketing Automation Software ©